Compare Summit Therapeutics Inc (SMMT) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance

Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.

The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.

VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.69, showing minimal daily movement with a slight 0.07% decline. The technical picture remains bearish with moving averages signaling caution, though oscillators are neutral. The fund provides international real estate diversification with 682 holdings across 30+ countries, featuring a low 0.12% expense ratio and attractive 4.6% dividend yield. Recent analysis highlights its role as a cost-effective diversifier for U.S.-focused real estate portfolios.

VNQI offers exposure to recovering global real estate markets with transaction volumes expected to grow over 10% in 2026. The fund trades at attractive valuations (0.9x P/B, 11.9x P/E) but faces headwinds from international market volatility and currency risks. While providing yield advantages over domestic peers, its total returns have lagged, making it suitable for investors seeking international diversification and income rather than growth leadership.